ORIC Pharmaceuticals Statistics
Share Statistics
ORIC Pharmaceuticals has 70.57M shares outstanding. The number of shares has increased by 29.31% in one year.
| Shares Outstanding | 70.57M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 4.63% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 42.14M |
| Failed to Deliver (FTD) Shares | 13 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 11.65M, so 16.51% of the outstanding shares have been sold short.
| Short Interest | 11.65M |
| Short % of Shares Out | 16.51% |
| Short % of Float | 25.3% |
| Short Ratio (days to cover) | 29.34 |
Valuation Ratios
The PE ratio is -4.7 and the forward PE ratio is -5.05.
| PE Ratio | -4.7 |
| Forward PE | -5.05 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 2.11 |
| P/FCF Ratio | -5.47 |
| PEG Ratio | n/a |
Enterprise Valuation
ORIC Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 10.39, with a Debt / Equity ratio of 0.
| Current Ratio | 10.39 |
| Quick Ratio | 10.39 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.45% and return on capital (ROIC) is -47.28%.
| Return on Equity (ROE) | -0.45% |
| Return on Assets (ROA) | -0.4% |
| Return on Capital (ROIC) | -47.28% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -899.08K |
| Employee Count | 112 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -8.59% in the last 52 weeks. The beta is 1.12, so ORIC Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.12 |
| 52-Week Price Change | -8.59% |
| 50-Day Moving Average | 9.39 |
| 200-Day Moving Average | 9.96 |
| Relative Strength Index (RSI) | 37.41 |
| Average Volume (20 Days) | 421.96K |
Income Statement
In the last 12 months, ORIC Pharmaceuticals had revenue of $0 and earned -$100.70M in profits. Earnings per share was $-1.96.
| Revenue | 0 |
| Gross Profit | -1.03M |
| Operating Income | -110.78M |
| Net Income | -100.70M |
| EBITDA | -109.75M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.96 |
Balance Sheet
The company has $23.38M in cash and $10.21M in debt, giving a net cash position of $13.17M.
| Cash & Cash Equivalents | 23.38M |
| Total Debt | 10.21M |
| Net Cash | 13.17M |
| Retained Earnings | -434.93M |
| Total Assets | 302.07M |
| Working Capital | 258.18M |
Cash Flow
In the last 12 months, operating cash flow was -$85.69M and capital expenditures -$849.00K, giving a free cash flow of -$86.54M.
| Operating Cash Flow | -85.69M |
| Capital Expenditures | -849.00K |
| Free Cash Flow | -86.54M |
| FCF Per Share | -1.68 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ORIC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -23.03% |
| FCF Yield | -14.41% |
Analyst Forecast
The average price target for ORIC is $19, which is 123.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $19 |
| Price Target Difference | 123.3% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 9.83 |
| Piotroski F-Score | 3 |